跳至主要内容
临床试验/NCT00134745
NCT00134745已完成4 期

The Growth of Genitalia Interna and the Bone Mineralization Under Hormonal Replacement Therapy and the Presence of Aortic Root Dilatation in Girls With Turner Syndrome

Line Cleemann1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2005年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
43
试验地点
1
主要终点
The size of the uterus evaluated by magnetic resonance (MR)-scan

研究概览

简要总结

The purpose of this study is to examine whether a larger dosage of estrogen than the one used today will secure the development of a normal sized uterus and increase the strength of the bones in girls and young women with Turner syndrome.

The purpose is also to evaluate whether aortic dilatation is present in this group of patients, and if the estrogen dosage will influence the emotional well-being and self-esteem of the patients.

详细描述

Turner syndrome is a common chromosomal disorder with only one X-chromosome or partial deletions in one X-chromosome in all or some of the cell-lines in the body. Appr. 18 girls/year are being born with the syndrome in Denmark. The syndrome is mostly known for reduced final height and the lack of pubertal development with infertility, but it is also known for diseases influencing other parts of the body like the heart with the risk of development of aortic dilatation and subsequently dissection with the risk of rupture, profuse bleeding and sudden death. Reduced bone strength and increased risk of bone fracture are also features of the syndrome. Treatment with growth hormone and female sex-hormones are well-established treatments.

Girls and young women with Turner syndrome ages 10 to 21 years will participate. The girls ages 15 to 21 years will randomly and double blindly receive treatment with either 2 mg or 4 mg estrogen for 5 years. Yearly examinations with blood tests, physical examinations, questionnaires, ultrasound and MR-scan of the internal female genitalia, DEXA-scan of the bones and MR-scan of the heart will be performed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
10 Years 至 25 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Verified Turner syndrome
  • Ages 10-25 years

排除标准

  • Contraindications to the MR-scan
  • Contraindications to the trial medication
  • Severe or chronic sickness with impact on the parameters of the study or incompatibility with the trial medication
  • Intake of medications with interactions with trial medication

研究组 & 干预措施

4 mg estradiol

Active Comparator

干预措施: estradiol (Drug)

2 mg estradiol

Placebo Comparator

干预措施: estradiol (Drug)

结局指标

主要结局

The size of the uterus evaluated by magnetic resonance (MR)-scan

时间窗: 5 years

Bones evaluated by dual-energy X-ray absorptiometry (DEXA)-scan

时间窗: 5 years

次要结局

  • The diameter of the aortic root evaluated by MR-scan(5 years)
  • Development of biochemical markers(5 years)
  • Body composition evaluated by DEXA-scan(5 years)
  • Emotional wellbeing and self-esteem evaluated by questionnaires(5 years)
  • The size of the uterus evaluated by ultrasound(5 years)

研究者

发起方
Line Cleemann
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Line Cleemann

Doctor, PhD

Hillerod Hospital, Denmark

研究点 (1)

Loading locations...

相似试验